CSRXP: HOUSE MARKUPS ADD TO UNPRECEDENTED MOMENTUM TO HOLD BIG PHARMA ACCOUNTABLE

Committee Leaders Put Forward Solutions to Lower Prescription Drug Prices for Patients, Seniors and Taxpayers Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a

09-14-2021 Read More

CSRXP APPLAUDS RELEASE OF HHS PLAN TO LOWER PRESCRIPTION DRUG PRICES AND HOLD BIG PHARMA ACCOUNTABLE

Administration Proposal Would Increase Competition, Transparency and Value — Reform Medicare Part D to Protect Seniors and Taxpayers Washington, D.C. – The Campaign for Sustainable Rx Pricing

09-9-2021 Read More

CSRXP APPLAUDS PRESIDENT BIDEN’S COMMITMENT TO LOWERING PRESCRIPTION DRUG PRICES AND CALL FOR CONGRESS TO ACT

Speech Adds to Unprecedented Momentum for Action, Now Lawmakers Must Deliver on Repeated Promises to Hold Big Pharma Accountable For Immediate Release Contact: Jon Conradi 860-235-3884

08-12-2021 Read More

CSRXP STATEMENT ON U.S. SENATE PASSAGE OF REBATE RULE DELAY & REFUND ACT AS PART OF BIPARTISAN INFRASTRUCTURE BILL

Lawmakers Must Build on Momentum For Action With Permanent Repeal of Rebate Rule and Solutions to Hold Big Pharma Accountable and Lower Drug Prices For Immediate Release Contact: Jon Conradi

08-10-2021 Read More

SECOND OPINION: BIG PHARMA TROTS OUT BOGUS R&D DEFENSE TO OPPOSE TAX

Remembering Drug Companies Spend Their Profits on Shareholders and Marketing — And Price Hikes Are Unrelated to Innovation A recent Wall Street Journal article, “Big Pharma Quietly Pushes Back

08-9-2021 Read More

BIG PHARMA EARNINGS WATCH: ASTRAZENECA, SANOFI, MERCK, ABBVIE, ELI LILLY & AMGEN

Q2 Earnings Reports Continue to Show Pandemic Price Hikes Profitable for Brand Name Drug Makers Another round of second quarter earnings reports from brand name drug makers AstraZeneca, Sanofi, Merck

08-6-2021 Read More

BIG PHARMA EARNINGS WATCH: PFIZER, GLAXO SMITH KLINE, BRISTOL MYERS SQUIBB

Big Pharma Companies Continue to Rake in Massive Profits After Three Rounds of Price Hikes During Pandemic Brand name drug makers Pfizer, Bristol Myers Squibb, and GlaxoSmithKline (GSK) held

07-30-2021 Read More

CSRXP WELCOMES FDA APPROVAL OF FIRST INTERCHANGEABLE BIOLOGIC FOR INSULIN

Interchangeable Products Will Help Increase Prescription Drug Competition and Provide More Affordable Alternatives For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected]

07-29-2021 Read More

CSRXP: SENATE JUDICIARY COMMITTEE CRACKS DOWN ON BIG PHARMA PATENT ABUSE

Unanimous, Bipartisan Passage of Bills Targeting Brand Name Drug Companies’ Anti-Competitive Tactics Adds to Momentum on Capitol Hill to Lower Rx Prices For Immediate Release Contact: Jon Conradi

07-29-2021 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.